

Markus Peck-Radosavljevic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2680614/publications.pdf>

Version: 2024-02-01

253
papers

16,116
citations

14653
66
h-index

19188
118
g-index

258
all docs

258
docs citations

258
times ranked

16742
citing authors

#	ARTICLE	IF	CITATIONS
1	MAFLD, HCC and the dilemma of (changing) terminology in liver diseases. <i>Gut</i> , 2023, 72, 9-11.	12.1	6
2	Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFTY score. <i>Journal of Hepatology</i> , 2022, 76, 353-363.	3.7	132
3	Splenectomy ameliorates portal pressure and anemia in animal models of cirrhotic and non-cirrhotic portal hypertension. <i>Advances in Medical Sciences</i> , 2022, 67, 154-162.	2.1	4
4	Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study. <i>Liver International</i> , 2022, 42, 1891-1901.	3.9	11
5	Changing Epidemiological Trends of Hepatobiliary Carcinomas in Austria 2010–2018. <i>Cancers</i> , 2022, 14, 3093.	3.7	5
6	Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. <i>Gut</i> , 2021, 70, 204-214.	12.1	150
7	Systemic therapy of advanced hepatocellular carcinoma. <i>Future Oncology</i> , 2021, 17, 1237-1251.	2.4	31
8	The prevalence of cirrhotic cardiomyopathy according to different diagnostic criteria. <i>Liver International</i> , 2021, 41, 1058-1069.	3.9	30
9	Perceptions on the management of varices and on the use of albumin in patients with cirrhosis among GI specialists in Austria. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 421-431.	1.9	4
10	The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model. <i>Biomedicines</i> , 2021, 9, 60.	3.2	37
11	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	27.8	649
12	Challenges in hepatitis C elimination despite highly effective antiviral agents in patients with and without intravenous drug use. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 641-646.	1.9	4
13	The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes. <i>Hepatology International</i> , 2021, 15, 1160-1173.	4.2	12
14	COVID-19 and digestive health: Implications for prevention, care and the use of COVID-19 vaccines in vulnerable patients. <i>United European Gastroenterology Journal</i> , 2021, 9, 1091-1095.	3.8	8
15	The bleeding risk after endoscopic ultrasound-guided puncture of pancreatic masses. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 205-210.	1.5	5
16	Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis. <i>United European Gastroenterology Journal</i> , 2021, 9, 1119-1127.	3.8	20
17	MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1080-1089.	3.7	19
18	Dynamics of platelet count after sustained virologic response do not mirror those of hepatic venous pressure gradient. <i>Liver International</i> , 2020, 40, 988-989.	3.9	6

#	ARTICLE	IF	CITATIONS
19	Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 313-327.e6.	4.4	74
20	Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy. <i>Hepatology</i> , 2020, 71, 1023-1036.	7.3	112
21	Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. <i>Hepatology</i> , 2020, 72, 198-212.	7.3	92
22	Securing sustainable funding for viral hepatitis elimination plans. <i>Liver International</i> , 2020, 40, 260-270.	3.9	24
23	Impact of <i>HSD17B13</i> rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension. <i>Liver International</i> , 2020, 40, 393-404.	3.9	20
24	Digestive health in Europe – lack of concerted action, exposed by COVID-19, starts with lack of uniform data reporting in liver disease. <i>Infectious Diseases</i> , 2020, 52, 828-829.	2.8	1
25	Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy. <i>Journal of Visualized Experiments</i> , 2020, , .	0.3	51
26	Transforming Growth Factor- β and Axl Induce CXCL5 and Neutrophil Recruitment in Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 222-236.	7.3	85
27	Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 71, 1164-1174.	3.7	249
28	Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2019, 7, 850-858.	3.8	18
29	A systematic literature review on the use of platelet transfusions in patients with thrombocytopenia. <i>Hematology</i> , 2019, 24, 679-719.	1.5	18
30	DAA's prevent HCC – the plot thickens. <i>Digestive and Liver Disease</i> , 2019, 51, 460-461.	0.9	0
31	Transjugular aspiration liver biopsy performed by hepatologists trained in HVPG measurements is safe and provides important diagnostic information. <i>Digestive and Liver Disease</i> , 2019, 51, 1144-1151.	0.9	23
32	Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1323-1333.	3.7	106
33	Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019, 8, 203-217.	7.7	48
34	Dysbalanced sex hormone status is an independent predictor of decompensation and mortality in patients with liver cirrhosis. <i>Hepatology Research</i> , 2019, 49, 201-211.	3.4	16
35	Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension. <i>Liver International</i> , 2018, 38, 1427-1436.	3.9	31
36	Monitoring the Evolution of Portal Hypertension After Sustained Virologic Response. <i>Gastroenterology</i> , 2018, 154, 1550-1551.	1.3	9

#	ARTICLE	IF	CITATIONS
37	ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis. <i>Liver International</i> , 2018, 38, 1036-1044.	3.9	28
38	Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfecting patients. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 105-114.	1.9	14
39	Point Shear Wave Elastography for Non-invasive Assessment of Liver Fibrosis in Patients with Viral Hepatitis. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 2578-2586.	1.5	11
40	Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with <i>RAS</i> -Mutated Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 4650-4661.	7.0	63
41	The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats. <i>Scientific Reports</i> , 2018, 8, 9372.	3.3	39
42	Review article: systemic treatment of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 598-609.	3.7	131
43	Noninvasive Monitoring of Liver Disease Regression after Hepatitis C Eradication Using Gadoteric Acid-Enhanced MRI. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-9.	0.8	7
44	Liver disease in adults with α_1 -antitrypsin deficiency. <i>United European Gastroenterology Journal</i> , 2018, 6, 710-718.	3.8	23
45	Young gastrointestinal angle: How to prepare and submit a job application. <i>United European Gastroenterology Journal</i> , 2018, 6, 160-161.	3.8	0
46	Transjugular intrahepatic portosystemic shunts (TIPS) for the prevention of variceal re-bleeding – A two decades experience. <i>PLoS ONE</i> , 2018, 13, e0189414.	2.5	20
47	Impact of glutathione peroxidase 4 on cell proliferation, angiogenesis and cytokine production in hepatocellular carcinoma. <i>Oncotarget</i> , 2018, 9, 10054-10068.	1.8	25
48	Daclatasvir plus Sofosbuvir, with or without Ribavirin, in Real-World Patients with HIV-HCV Coinfection and Advanced Liver Disease. <i>Antiviral Therapy</i> , 2017, 22, 225-236.	1.0	26
49	Plasma renin concentration represents an independent risk factor for mortality and is associated with liver dysfunction in patients with cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 184-190.	2.8	17
50	Prevention of progression from small to large varices: are we there yet? An updated meta-analysis. <i>Gut</i> , 2017, 66, 1347-1349.	12.1	22
51	Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 1-8.	1.5	13
52	Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2017, 5, 987-996.	3.8	49
53	Type I interferon as a biomarker in autoimmunity and viral infection: a leukocyte subset-specific analysis unveils hidden diagnostic options. <i>Journal of Molecular Medicine</i> , 2017, 95, 753-765.	3.9	19
54	Real-world experience with daclatasvir plus sofosbuvir \pm ribavirin for post-liver transplant HCV recurrence and severe liver disease. <i>Transplant International</i> , 2017, 30, 243-255.	1.6	19

#	ARTICLE	IF	CITATIONS
55	The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. <i>Journal of Hepatology</i> , 2017, 66, 724-733.	3.7	130
56	Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth-III). <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 135-158.	1.9	111
57	Differentiation of Intrahepatic Cholangiocellular Carcinoma from Hepatocellular Carcinoma in the Cirrhotic Liver Using Contrast-enhanced MR Imaging. <i>Academic Radiology</i> , 2017, 24, 1491-1500.	2.5	13
58	Re-bleeding rates and survival after early transjugular intrahepatic portosystemic shunt (TIPS) in clinical practice. <i>Digestive and Liver Disease</i> , 2017, 49, 1360-1367.	0.9	28
59	Effects of Portal Hypertension on Gadolinium-Enhanced Liver Magnetic Resonance. <i>Investigative Radiology</i> , 2017, 52, 462-469.	6.2	14
60	The value of [11C]-acetate PET and [18F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1732-1741.	6.4	20
61	Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna. <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 517-526.	1.9	9
62	Thrombocytopenia in chronic liver disease. <i>Liver International</i> , 2017, 37, 778-793.	3.9	183
63	Treatment With Ledipasvir/Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection. <i>Annals of Internal Medicine</i> , 2017, 166, 109.	3.9	164
64	Low 25-OH-vitamin D levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosis. <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 8-15.	1.9	44
65	Oxidative stress mediates an increased formation of vascular endothelial growth factor in human hepatocarcinoma cells exposed to erlotinib. <i>Oncotarget</i> , 2017, 8, 57109-57120.	1.8	5
66	The impact of thyroid hormones on patients with hepatocellular carcinoma. <i>PLoS ONE</i> , 2017, 12, e0181878.	2.5	24
67	Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant. <i>Annals of Hepatology</i> , 2017, 16, 375-381.	1.5	1
68	Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease. <i>Aids</i> , 2016, 30, 1039-1047.	2.2	42
69	The trigger matters – outcome of hepatorenal syndrome vs. specifically triggered acute kidney injury in cirrhotic patients with ascites. <i>Liver International</i> , 2016, 36, 1649-1656.	3.9	10
70	Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. <i>Gut</i> , 2016, 65, 1861-1870.	12.1	166
71	Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease. <i>Medicine (United States)</i> , 2016, 95, e4061.	1.0	18
72	Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. <i>Journal of Hepatology</i> , 2016, 65, 692-699.	3.7	245

#	ARTICLE	IF	CITATIONS
73	Indications for liver transplantation in adults. Wiener Klinische Wochenschrift, 2016, 128, 679-690.	1.9	39
74	von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy. Digestive and Liver Disease, 2016, 48, 1194-1199.	0.9	1
75	Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open, 2016, 1, e000042.	4.5	194
76	Treatment intensification with boceprevir in HIV-positive patients with acute HCV-genotype 1 infection at high risk for treatment failure. Wiener Klinische Wochenschrift, 2016, 128, 414-420.	1.9	1
77	Endoscopic versus surgical management of biliary complications – Outcome analysis after 1188 orthotopic liver transplantations. Digestive and Liver Disease, 2016, 48, 1323-1329.	0.9	10
78	Advances in the management of HIV/HCV coinfection. Hepatology International, 2016, 10, 424-435.	4.2	47
79	Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infectious Diseases, The, 2016, 16, 685-697.	9.1	402
80	Prognosis of cirrhotic patients with fungiascites and spontaneous fungal peritonitis (SFP). Journal of Hepatology, 2016, 64, 1452-1454.	3.7	13
81	Antiviral Treatments and Residual Risk of Hepatic Decompensation. , 2016, , 99-104.		0
82	Interferon-free antiviral treatment of chronic hepatitis C in the transplant setting. Transplant International, 2015, 28, 1011-1024.	1.6	10
83	Impact of acute kidney injury on prognosis of patients with liver cirrhosis and ascites: A retrospective cohort study. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1657-1665.	2.8	37
84	Evaluation of a new balloon occlusion catheter specifically designed for measurement of hepatic venous pressure gradient. Liver International, 2015, 35, 2115-2120.	3.9	54
85	Performance of 2-D Shear Wave Elastography in Liver Fibrosis Assessment Compared with Serologic Tests and Transient Elastography in Clinical Routine. Ultrasound in Medicine and Biology, 2015, 41, 2340-2349.	1.5	23
86	Neuropilin-2 induced by transforming growth factor- β augments migration of hepatocellular carcinoma cells. BMC Cancer, 2015, 15, 909.	2.6	30
87	50 years of EASL – From a European to a global perspective. Journal of Hepatology, 2015, 62, 4-5.	3.7	4
88	Axl activates autocrine transforming growth factor- β signaling in hepatocellular carcinoma. Hepatology, 2015, 61, 930-941.	7.3	127
89	Response-Guided Boceprevir-based Triple Therapy in HIV/HCV-coinfected Patients: The HIVCOBOC-RGT Study. Journal of Infectious Diseases, 2015, 211, 729-735.	4.0	10
90	Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites. Liver International, 2015, 35, 2121-2128.	3.9	72

#	ARTICLE	IF	CITATIONS
91	30years of the Journal of Hepatology – The flagship journal and the crown-jewel of EASL. Journal of Hepatology, 2015, 62, S4-S5.	3.7	1
92	Transarterial chemoembolization: Modalities, indication, and patient selection. Journal of Hepatology, 2015, 62, 1187-1195.	3.7	250
93	New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension. Liver International, 2015, 35, 381-390.	3.9	111
94	Expression of vasoactive proteins in gastric antral mucosa reflects vascular dysfunction in patients with cirrhosis and portal hypertension. Liver International, 2015, 35, 1393-1402.	3.9	10
95	Platelet Dysfunction: Status of Thrombopoietin in Thrombocytopenia Associated with Chronic Liver Failure. Seminars in Thrombosis and Hemostasis, 2015, 41, 455-461.	2.7	14
96	Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo. Radiology, 2015, 277, 903-912.	7.3	60
97	Managing complications in cirrhotic patients. United European Gastroenterology Journal, 2015, 3, 80-94.	3.8	9
98	Revisiting liver disease progression in HIV/HCV-coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3. Liver International, 2015, 35, 876-885.	3.9	32
99	Randomized phase II trial comparing the efficacy and safety of nintedanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2015, 33, 238-238.	1.6	7
100	Circulating MiRNA-122 Levels Are Associated with Hepatic Necroinflammation and Portal Hypertension in HIV/HCV Coinfection. PLoS ONE, 2015, 10, e0116768.	2.5	21
101	The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection. PLoS ONE, 2015, 10, e0143429.	2.5	23
102	Efficacy and safety of nintedanib (N) versus sorafenib (S) in Caucasian and Asian patients with advanced hepatocellular carcinoma (HCC): Pooled analysis of two randomized phase II trials.. Journal of Clinical Oncology, 2015, 33, 4074-4074.	1.6	0
103	Strategies for Assignment of HIV-HCV Genotype-1-Coinfected Patients to Either Dual-Therapy or Direct-Acting Antiviral Agent-Based Triple-Therapy. Antiviral Therapy, 2014, 19, 407-414.	1.0	5
104	PRO-C3-Levels in Patients with HIV/HCV-Co-Infection Reflect Fibrosis Stage and Degree of Portal Hypertension. PLoS ONE, 2014, 9, e108544.	2.5	29
105	Entering a new era in the treatment of hepatitis C. Digestive and Liver Disease, 2014, 46, S157.	0.9	0
106	Epidemiological Trends of Hepatocellular Carcinoma in Austria. Digestive Diseases, 2014, 32, 664-669.	1.9	10
107	Incidence and mortality trends for biliary tract cancers in Austria. Liver International, 2014, 34, 1102-1108.	3.9	31
108	Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib. JAMA - Journal of the American Medical Association, 2014, 312, 57.	7.4	515

#	ARTICLE	IF	CITATIONS
109	Nonselective β^2 Blockers Increase Risk for Hepatorenal Syndrome and Death in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis. <i>Gastroenterology</i> , 2014, 146, 1680-1690.e1.	1.3	336
110	The ART-strategy: Sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. <i>Journal of Hepatology</i> , 2014, 60, 118-126.	3.7	105
111	Health-related quality of life and severity of fatigue in <scp>HIV</scp>/<scp>HCV</scp> co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin. <i>Liver International</i> , 2014, 34, 69-77.	3.9	35
112	How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014, 61, 1287-1296.	3.7	139
113	Reply. <i>Hepatology</i> , 2014, 59, 2425-2426.	7.3	0
114	Reply. <i>Gastroenterology</i> , 2014, 147, 942.	1.3	1
115	Therapeutic Potential of and Treatment with Boceprevir/Telaprevir-Based Triple-Therapy in HIV/Chronic Hepatitis C Co-Infected Patients in a Real-World Setting. <i>AIDS Patient Care and STDs</i> , 2014, 28, 221-227.	2.5	11
116	EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation. <i>Nature Cell Biology</i> , 2014, 16, 972-981.	10.3	198
117	Go East. <i>Journal of Hepatology</i> , 2014, 60, 4-5.	3.7	5
118	Reply to the Letters to the Editor regarding the sequential ART-Score. <i>Journal of Hepatology</i> , 2014, 61, 177-178.	3.7	2
119	Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats. <i>Journal of Hepatology</i> , 2014, 60, 1135-1142.	3.7	39
120	Drug Therapy for Advanced-Stage Liver Cancer. <i>Liver Cancer</i> , 2014, 3, 125-131.	7.7	70
121	EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib.. <i>Journal of Clinical Oncology</i> , 2014, 32, 172-172.	1.6	26
122	Proton Pump Inhibitor Intake neither Predisposes to Spontaneous Bacterial Peritonitis or Other Infections nor Increases Mortality in Patients with Cirrhosis and Ascites. <i>PLoS ONE</i> , 2014, 9, e110503.	2.5	55
123	Reply. <i>Hepatology</i> , 2013, 58, 1189-1190.	7.3	0
124	Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling. <i>Liver International</i> , 2013, 33, 561-568.	3.9	16
125	Portale Hypertension. <i>Wiener Klinische Wochenschrift Education</i> , 2013, 8, 1-13.	0.0	0
126	The burden of liver disease in Europe: A review of available epidemiological data. <i>Journal of Hepatology</i> , 2013, 58, 593-608.	3.7	1,089

#	ARTICLE	IF	CITATIONS
127	The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. <i>Hepatology</i> , 2013, 57, 2261-2273.	7.3	288
128	The influence of aminotransferase levels on liver stiffness assessed by Acoustic Radiation Force Impulse Elastography: A retrospective multicentre study. <i>Digestive and Liver Disease</i> , 2013, 45, 762-768.	0.9	76
129	Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. <i>Journal of Hepatology</i> , 2013, 58, 911-921.	3.7	269
130	Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II). <i>Wiener Klinische Wochenschrift</i> , 2013, 125, 200-219.	1.9	43
131	Meta-analysis: <sc>ARFI</sc> elastography versus transient elastography for the evaluation of liver fibrosis. <i>Liver International</i> , 2013, 33, 1138-1147.	3.9	370
132	Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma. <i>Hepatology</i> , 2013, 57, 2224-2234.	7.3	101
133	Hedgehog inhibition reduces angiogenesis by downregulation of tumoral VEGF expression in hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2013, 1, 265-275.	3.8	26
134	Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. <i>Gut</i> , 2013, 62, 1634-1641.	12.1	275
135	The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients. <i>Aids</i> , 2013, 27, 2707-2714.	2.2	15
136	Low vitamin D levels are associated with impaired virologic response to PEGIFN+RBV therapy in HIV+hepatitis C virus coinfected patients. <i>Aids</i> , 2013, 27, 227-232.	2.2	39
137	Variation in Both IL28B and KIR2DS3 Genes Influence Pegylated Interferon and Ribavirin Hepatitis C Treatment Outcome in HIV-1 Co-Infection. <i>PLoS ONE</i> , 2013, 8, e66831.	2.5	12
138	A Prospective Evaluation of Pulmonary, Systemic and Hepatic Haemodynamics in HIV+HCV-Coinfected Patients before and after Antiviral Therapy with Pegylated Interferon and Ribavirin. <i>Antiviral Therapy</i> , 2012, 17, 1327-1334.	1.0	27
139	<sc>BCLC</sc> – now also an internationally acclaimed prognostic system?. <i>Liver International</i> , 2012, 32, 1037-1038.	3.9	1
140	Back to basics: Staging and prognosis in HCC for medical oncologist. <i>Journal of Hepatology</i> , 2012, 56, 488-489.	3.7	7
141	The “pegylated” story continues – Perhaps because both ends (1±2a and 1±2b) are true?. <i>Journal of Hepatology</i> , 2012, 57, 226-228.	3.7	0
142	Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 57, 592-599.	3.7	28
143	Von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. <i>Hepatology</i> , 2012, 56, 1439-1447.	7.3	158
144	Advanced-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization versus Sorafenib. <i>Radiology</i> , 2012, 263, 590-599.	7.3	177

#	ARTICLE	IF	CITATIONS
145	Acoustic Radiation Force Impulse Elastography for fibrosis evaluation in patients with chronic hepatitis C: An international multicenter study. <i>European Journal of Radiology</i> , 2012, 81, 4112-4118.	2.6	156
146	Antagonistic effects of selenium and lipid peroxides on growth control in early hepatocellular carcinoma. <i>Hepatology</i> , 2012, 55, 1112-1121.	7.3	52
147	Advances in haematology and oncology 2011: hepatocellular carcinoma (HCC). <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 161-162.	0.5	0
148	Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study. <i>European Radiology</i> , 2012, 22, 1214-1223.	4.5	41
149	Austrian Joint A-GGH-Ä-GIR-Ä-GHO-ASSO position statement on the use of transarterial chemoembolization (TACE) in hepatocellular carcinoma. <i>Wiener Klinische Wochenschrift</i> , 2012, 124, 104-110.	1.9	14
150	Noninvasive screening for liver fibrosis and portal hypertension by transient elastography—a large single center experience. <i>Wiener Klinische Wochenschrift</i> , 2012, 124, 395-402.	1.9	93
151	IL28B and interferon-γ inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV/HCV coinfected patients. <i>European Journal of Clinical Investigation</i> , 2012, 42, 599-606.	3.4	27
152	Hepatitis B Surface Antigen Concentrations in Patients with HIV/HBV Co-Infection. <i>PLoS ONE</i> , 2012, 7, e43143.	2.5	42
153	Comparative outcome of sorafenib treatment in central Europe and Russia.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14681-e14681.	1.6	0
154	Portal Pressure Predicts Outcome and Safety of Antiviral Therapy in Cirrhotic Patients With Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 602-608.e1.	4.4	57
155	Low-Dose Peginterferon Alfa-2a Is Safe and Produces a Sustained Virologic Response in Patients With Chronic Hepatitis C and End-Stage Renal Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 242-248.	4.4	28
156	Osteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteria. <i>Journal of Hepatology</i> , 2011, 54, 89-97.	3.7	39
157	Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 212-223.	17.8	119
158	Considerable Under-Treatment of Chronic HCV Infection in HIV Patients despite Acceptable Sustained Virological Response Rates in a Real-Life Setting. <i>Antiviral Therapy</i> , 2011, 16, 815-824.	1.0	31
159	NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer. <i>Surgery</i> , 2011, 149, 311-320.	1.9	101
160	Sorafenib in unresectable intrahepatic cholangiocellular carcinoma: a case report. <i>Wiener Klinische Wochenschrift</i> , 2011, 123, 61-64.	1.9	9
161	Clinical characteristics of patients with hepatocellular carcinoma in Austria – is there a need for a structured screening program?. <i>Wiener Klinische Wochenschrift</i> , 2011, 123, 542-551.	1.9	51
162	HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension. <i>Journal of Viral Hepatitis</i> , 2010, 17, 400-409.	2.0	64

#	ARTICLE	IF	CITATIONS
163	Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 391-398.	1.6	60
164	Hepatocyte IKK β /NF- κ B Inhibits Tumor Promotion and Progression by Preventing Oxidative Stress-Driven STAT3 Activation. <i>Cancer Cell</i> , 2010, 17, 286-297.	16.8	405
165	TACE it or leave it: hard choices for intermediate-stage hepatocellular carcinoma patients beyond perfect health. <i>Liver International</i> , 2010, 30, 3-4.	3.9	0
166	A double-blind, randomized, placebo-controlled trial of intravenous l-ornithine-l-aspartate on postural control in patients with cirrhosis. <i>Liver International</i> , 2010, 30, 574-582.	3.9	31
167	Research update for articles published in EJC in 2008. <i>European Journal of Clinical Investigation</i> , 2010, 40, 770-789.	3.4	1
168	von Willebrand Factor Antigen: A Novel On-Treatment Predictor of Response to Antiviral Therapy in Chronic Hepatitis C Genotypes 1 and 4. <i>Antiviral Therapy</i> , 2010, 15, 831-839.	1.0	12
169	Review: Hepatocellular carcinoma: the place of new medical therapies. <i>Therapeutic Advances in Gastroenterology</i> , 2010, 3, 259-267.	3.2	9
170	Mitochondrial Toxicity Is Associated with Virological Response in Patients with HIV and Hepatitis C Virus Coinfection Treated with Ribavirin and Highly Active Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2010, 202, 156-160.	4.0	17
171	Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV/HCV coinfecting patient. <i>Journal of Clinical Virology</i> , 2010, 49, 131-133.	3.1	54
172	Nuclear β -Catenin Induces an Early Liver Progenitor Phenotype in Hepatocellular Carcinoma and Promotes Tumor Recurrence. <i>American Journal of Pathology</i> , 2010, 176, 472-481.	3.8	97
173	Sorafenib in Unresectable Hepatocellular Carcinoma from Mild to Advanced Stage Liver Cirrhosis. <i>Oncologist</i> , 2009, 14, 70-76.	3.7	169
174	Das hepatozelluläre Karzinom. <i>Wiener Klinische Wochenschrift</i> Education, 2009, 4, 33-41.	0.0	0
175	Aetiology of cirrhosis of the liver has an impact on survival predicted by the Model of End-stage Liver Disease score. <i>European Journal of Clinical Investigation</i> , 2009, 39, 65-71.	3.4	15
176	Pregnancy in women with known and treated Budd-Chiari syndrome: Maternal and fetal outcomes. <i>Journal of Hepatology</i> , 2009, 51, 47-54.	3.7	85
177	Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. <i>Journal of Hepatology</i> , 2009, 51, 865-873.	3.7	95
178	Differential role of circulating endothelial progenitor cells in cirrhotic patients with or without hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2009, 41, 902-906.	0.9	28
179	Octreotide treatment of patients with hepatocellular carcinoma - a retrospective single centre controlled study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009, 28, 142.	8.6	6
180	Postural control in patients with liver cirrhosis: a posturographic study. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 915-922.	1.6	5

#	ARTICLE	IF	CITATIONS
181	Portale Hypertension. Wiener Klinische Wochenschrift Education, 2008, 3, 107-118.	0.0	0
182	Percutaneous ethanol instillation therapy for hepatocellular carcinoma – a randomized controlled trial. Wiener Klinische Wochenschrift, 2008, 120, 608-618.	1.9	3
183	Efficacy of interferon in immunocompromised HCV patients after liver transplantation or with HIV co-infection. European Journal of Clinical Investigation, 2008, 38, 421-429.	3.4	14
184	Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial. European Journal of Gastroenterology and Hepatology, 2008, 20, 1012-1019.	1.6	20
185	IP-10 Correlates with Hepatitis C Viral Load, Hepatic Inflammation and Fibrosis and Predicts Hepatitis C Virus Relapse or Non-Response in HIV/HCV Coinfection. Antiviral Therapy, 2008, 13, 969-976.	1.0	82
186	6-Thioguanine Associated Nodular Regenerative Hyperplasia in Patients With Inflammatory Bowel Disease May Induce Portal Hypertension. American Journal of Gastroenterology, 2007, 102, 2495-2503.	0.4	80
187	Mammalian Target of Rapamycin Pathway Activity in Hepatocellular Carcinomas of Patients Undergoing Liver Transplantation. Transplantation, 2007, 83, 425-432.	1.0	139
188	MR-guided percutaneous ethanol ablation of hepatocellular carcinomas before liver transplantation. Minimally Invasive Therapy and Allied Technologies, 2007, 16, 230-240.	1.2	3
189	An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transplantation, 2007, 13, 1174-1180.	2.4	216
190	Review article: coagulation disorders in chronic liver disease. Alimentary Pharmacology and Therapeutics, 2007, 26, 21-28.	3.7	61
191	Prophylactic Bisphosphonate Treatment Prevents Bone Fractures After Liver Transplantation. American Journal of Transplantation, 2007, 7, 1763-1769.	4.7	52
192	KiSS-1 overexpression as an independent prognostic marker in hepatocellular carcinoma: an immunohistochemical study. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 450, 143-149.	2.8	53
193	Mcl-1 overexpression in hepatocellular carcinoma: A potential target for antisense therapy. Journal of Hepatology, 2006, 44, 151-157.	3.7	217
194	Antiviral therapy decreases GpIIb/IIIa activation of platelets in patients with chronic hepatitis C. Thrombosis and Haemostasis, 2006, 95, 260-266.	3.4	6
195	Is MELD score sufficient to predict not only death on waiting list, but also post-transplant survival?. Transplant International, 2006, 19, 275-281.	1.6	49
196	Comparison of ¹¹ C-acetate positron emission tomography and ⁶⁷ Gallium citrate scintigraphy in patients with hepatocellular carcinoma. Liver International, 2006, 26, 920-927.	3.9	17
197	Portal hypertension – old problem, new therapeutic solutions. Wiener Medizinische Wochenschrift, 2006, 156, 397-403.	1.1	2
198	Platelet autoantibodies are common in hepatitis C infection, irrespective of the presence of thrombocytopenia. European Journal of Haematology, 2006, 77, 513-517.	2.2	48

#	ARTICLE	IF	CITATIONS
199	AEROBIC CAPACITY, MUSCLE STRENGTH AND HEALTH-RELATED QUALITY OF LIFE BEFORE AND AFTER ORTHOTOPIC LIVER TRANSPLANTATION: PRELIMINARY DATA OF AN AUSTRIAN TRANSPLANTATION CENTRE. <i>Journal of Rehabilitation Medicine</i> , 2006, 38, 322-328.	1.1	40
200	Erythropoietin Treatment Is Associated with More Severe Thrombocytopenia in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy. <i>American Journal of Gastroenterology</i> , 2006, 101, 2275-2282.	0.4	13
201	Platelet Count/Spleen Diameter Ratio for the Noninvasive Diagnosis of Esophageal Varices: Results of a Multicenter, Prospective, Validation Study. <i>American Journal of Gastroenterology</i> , 2006, 101, 2511-2519.	0.4	215
202	Platelet autoantibodies are common in hepatitis C infection, irrespective of the presence of thrombocytopenia. <i>European Journal of Haematology</i> , 2006, .	2.2	0
203	Vasoconstrictor hyporeactivity can be reversed by antioxidants in patients with advanced alcoholic cirrhosis of the liver and ascites. <i>Critical Care Medicine</i> , 2005, 33, 2028-2033.	0.9	29
204	Equilibrium of acidifying and alkalinizing metabolic acid-base disorders in cirrhosis.. <i>Liver International</i> , 2005, 25, 505-512.	3.9	29
205	Short- and long-term effects of therapy with interferon-alpha and pegylated interferon-alpha/ribavirin on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 49-55.	3.7	18
206	Arterial Embolization of Unresectable Hepatocellular Carcinoma with Use of Microspheres, Lipiodol, and Cyanoacrylate. <i>CardioVascular and Interventional Radiology</i> , 2005, 28, 313-318.	2.0	54
207	TIPS “ Relevant for Therapy of Variceal Bleeding?. <i>Visceral Medicine</i> , 2005, 21, 224-229.	1.3	0
208	Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon “ mono and combination therapy regimens. <i>Cut</i> , 2005, 54, 1014-1020.	12.1	59
209	Effects of TIPS on Liver Perfusion Measured by Dynamic CT. <i>American Journal of Roentgenology</i> , 2005, 184, 505-510.	2.2	39
210	Austrian Consensus on the Definition and Treatment of Portal Hypertension and its Complications. <i>Endoscopy</i> , 2005, 37, 667-673.	1.8	29
211	Pretransplant screening of sobriety with carbohydrate-deficient transferrin in patients suffering from alcoholic cirrhosis. <i>Transplant International</i> , 2004, 17, 617-621.	1.6	33
212	Erythropoietin increases platelet reactivity and platelet counts in patients with alcoholic liver cirrhosis: a randomized, double-blind, placebo-controlled study. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 437-443.	3.7	45
213	Transjugular intrahepatic portosystemic shunt in Vienna “ A decade later. <i>Wiener Klinische Wochenschrift</i> , 2004, 116, 608-613.	1.9	7
214	Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stents. <i>Hepatology</i> , 2003, 38, 1043-1050.	7.3	160
215	Effect of therapy with pegylated interferon“ on platelet activation and apoptosis in patients with chronic hepatitis C. <i>Gastroenterology</i> , 2003, 124, A768-A769.	1.3	0
216	Survival of patients undergoing TIPS: ePTFE-covered stent-grafts vs. bare-stents. <i>Gastroenterology</i> , 2003, 124, A734.	1.3	1

#	ARTICLE	IF	CITATIONS
217	Suppression of hematopoiesis during therapy with different IFN- α mono- and combination therapy regimes. <i>Gastroenterology</i> , 2003, 124, A780.	1.3	0
218	Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. <i>Gut</i> , 2003, 52, 879-885.	12.1	244
219	Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy. <i>Annals of Oncology</i> , 2003, 14, 1274-1277.	1.2	54
220	Mutations of the HFE gene in patients with hepatocellular carcinoma. <i>American Journal of Gastroenterology</i> , 2003, 98, 442-447.	0.4	51
221	Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stents. <i>Hepatology</i> , 2003, 38, 1043-1050.	7.3	90
222	Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. <i>American Journal of Gastroenterology</i> , 2002, 97, 2880-2885.	0.4	109
223	Transjugular intrahepatic portosystemic shunt for treatment of portal hypertension due to extramedullary hematopoiesis in idiopathic myelofibrosis. <i>Blood</i> , 2002, 99, 4246-4247.	1.4	25
224	Rapid suppression of hematopoiesis by standard or pegylated interferon- α . <i>Gastroenterology</i> , 2002, 123, 141-151.	1.3	122
225	Randomized, double-blind, placebo controlled trial of RHU-EPO to improve platelet count and platelet function in alcoholic cirrhotics with thrombocytopenia. <i>Journal of Hepatology</i> , 2002, 36, 12.	3.7	0
226	Child-PUGH- vs. meld-score to predict survival after tips: the Vienna-experience with 349 patients over 10 years. <i>Journal of Hepatology</i> , 2002, 36, 16.	3.7	2
227	Postural instability in patients with liver cirrhosis. <i>Journal of Hepatology</i> , 2002, 36, 62-63.	3.7	1
228	Ammonia and partial pressure of ammonia " correlation with postural control, Child-Pugh-stage and reitan a test in patients with cirrhosis. <i>Journal of Hepatology</i> , 2002, 36, 63.	3.7	0
229	Antagonisation of the antiproliferative action of IFN-alpha on megacaryocytic cell lines by thrombopoietin (TPO). <i>Journal of Hepatology</i> , 2002, 36, 75.	3.7	0
230	Hematological changes during IFN/ribavirin combination therapy in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2002, 36, 114-115.	3.7	0
231	Repeat Interventions for Maintenance of Transjugular Intrahepatic Portosystemic Shunt Function in Patients with Budd-Chiari Syndrome. <i>Journal of Vascular and Interventional Radiology</i> , 2002, 13, 193-199.	0.5	47
232	ePTFE-Covered Stent-Grafts for Revision of Obstructed Transjugular Intrahepatic Portosystemic Shunt. <i>CardioVascular and Interventional Radiology</i> , 2002, 25, 365-372.	2.0	38
233	Hypersplenism. <i>European Journal of Gastroenterology and Hepatology</i> , 2001, 13, 317-323.	1.6	87
234	Characterization of ^{123}I -vascular endothelial growth factor-binding sites expressed on human tumour cells: Possible implication for tumour scintigraphy. <i>International Journal of Cancer</i> , 2001, 91, 789-796.	5.1	66

#	ARTICLE	IF	CITATIONS
235	PHYSICAL PERFORMANCE AND HEALTH-RELATED QUALITY OF LIFE IN MEN ON A LIVER TRANSPLANTATION WAITING LIST. Journal of Rehabilitation Medicine, 2001, 33, 260-265.	1.1	46
236	Creation of Transjugular Intrahepatic Portosystemic Shunts with Stent-Grafts: Initial Experiences with a Polytetrafluoroethylene-covered Nitinol Endoprosthesis. Radiology, 2001, 221, 437-446.	7.3	105
237	UNDERLYING DISEASE AS A PREDICTOR FOR REJECTION AFTER LIVER TRANSPLANTATION.. Transplantation, 2000, 69, S164.	1.0	0
238	Thrombopoietin in Plasmodium falciparum malaria. British Journal of Haematology, 2000, 109, 534-536.	2.5	26
239	Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood, 2000, 95, 795-801.	1.4	177
240	Thrombocytopenia in Liver Disease. Canadian Journal of Gastroenterology & Hepatology, 2000, 14, 60D-66D.	1.7	156
241	Differential thrombopoietin response to treatment-induced thrombocytopenia: IFN VS. IFN-ribavirin VS. PEG-IFN. Gastroenterology, 2000, 118, A950.	1.3	1
242	DOTA-Lanreotide: A Novel Somatostatin Analog for Tumor Diagnosis and Therapy ¹ . Endocrinology, 1999, 140, 5136-5148.	2.8	76
243	Thrombopoietic cytokines and reversal of thrombocytopenia after liver transplantation. European Journal of Gastroenterology and Hepatology, 1999, 11, 151-156.	1.6	26
244	Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C. Hepatology, 1998, 28, 1424-1429.	7.3	92
245	Direct evidence for an increase in thrombopoiesis after liver transplantation. European Journal of Clinical Investigation, 1998, 28, 755-759.	3.4	22
246	Preoperative TNM-classification is a better prognostic indicator for recurrence of hepatocellular carcinoma after liver transplantation than albumin mRNA in peripheral blood. Journal of Hepatology, 1998, 28, 497-503.	3.7	14
247	Transjugular Intrahepatic Portosystemic Shunt and Cardiac Arrhythmias. Journal of Clinical Gastroenterology, 1998, 26, 39-43.	2.2	11
248	Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver?. Journal of Hepatology, 1997, 27, 127-131.	3.7	171
249	¹²³ I-vasoactive intestinal peptide (VIP) receptor scanning: Update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract. Nuclear Medicine and Biology, 1996, 23, 685-692.	0.6	51
250	Development of an avian model for restenosis. Atherosclerosis, 1996, 119, 17-41.	0.8	13
251	In vitro and in vivo studies of three radiolabelled somatostatin analogues: ¹²³ I-Octreotide (OCT), ¹²³ I-Tyr-3-OCT and ¹¹¹ In-TIRA-d-Phe-1-OCT. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 1388-1399.	2.1	31
252	Elevated levels of serum carbohydrate deficient transferrin are not specific for alcohol abuse in patients with liver disease. Journal of Hepatology, 1995, 23, 706-711.	3.7	27

#	ARTICLE	IF	CITATIONS
253	Hepatocellular carcinoma incidence in chronic hepatitis C patients according to sustained virological response (<scp>SVR</scp>) with interferon-based therapies and baseline characteristics. Liver Cancer International, 0, , .	1.3	0